Melanotan 2

Melanotan 2: Mechanism, Pharmacology & UK Status

Melanotan 2 is a synthetic cyclic lactam heptapeptide that acts as a non-selective agonist across the melanocortin receptor family (MC1R–MC5R), with its constrained Asp-Lys lactam bridge conferring superpotency and a markedly longer plasma half-life than linear α-MSH [1][4]. It remains unlicensed in the United Kingdom: the MHRA logged 16 suspected adverse drug reaction reports between 1 January 2012 and 31 December 2022 and recorded no specific regulatory action in response [3].

Key Takeaways

• Melanotan 2 is a cyclic heptapeptide agonist at melanocortin receptors MC1R–MC5R, unlicensed in the UK and sold only via illicit channels.
• The Asp⁵–Lys¹⁰ lactam bridge locks the pharmacophore into a β-turn conformation, extending plasma half-life and raising potency relative to linear α-MSH.
• Non-selective receptor engagement explains both the pigmentation effect (MC1R) and off-target effects: nausea and appetite changes (MC3R/MC4R), spontaneous erections (MC4R), and sebaceous changes (MC5R).
• The MHRA recorded 16 suspected adverse drug reaction reports between 2012 and 2022; no controlled human trials have been conducted.
• Afamelanotide (Scenesse) is the only licensed melanocortin analogue in the UK/EU, approved for erythropoietic protoporphyria.

What Is Melanotan 2? A Concise Definition

Melanotan 2 (MT-II) is a synthetic cyclic lactam heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH) that acts as a non-selective agonist at the melanocortin receptors MC1R–MC5R, with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ and the molecular formula C₅₀H₆₉N₁₅O₉ [2][4]. It is unlicensed in the United Kingdom and sold only via illicit channels [1][4].

The cyclisation comes from an amide bridge between the side chains of Asp⁵ and Lys¹⁰ of the parent linear template. This bridge locks the pharmacophore into a β-turn conformation that resists proteolysis and prolongs receptor residence relative to linear α-MSH [4]. That structural feature is what the early development literature called a "superpotent cyclic melanotropic peptide." It distinguishes MT-II pharmacologically from its precursors because the constrained backbone reduces the entropic cost of binding to melanocortin receptors.

MT-II versus Melanotan I (afamelanotide)

Melanotan 2 should not be conflated with Melanotan I. Melanotan I is afamelanotide (Scenesse), a linear 13-residue α-MSH analogue licensed by the EMA for erythropoietic protoporphyria — the only melanocortin agonist with an approved therapeutic indication in the UK/EU regulatory perimeter [2][4]. MT-II has no marketing authorisation in any major jurisdiction and exists in the research and grey-market space only [1][4].

For the wider structural rationale linking lactam constraint to receptor pharmacology, see our note on protein structures to peptide therapeutics, and our full peptides reference library for related compounds.

Molecular Structure: Cyclic Lactam vs Linear α-MSH

The pharmacological gap between MT-II and α-MSH comes directly from backbone topology. α-MSH is a linear tridecapeptide (Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂). MT-II is a heptapeptide closed into a 23-membered ring by a side-chain lactam between Asp⁵ and Lys¹⁰ of the parent template, giving Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂ [4].

Truncating the message sequence to the His-Phe-Arg-Trp core and locking it inside a covalent macrocycle converts a flexible hormone into a constrained, superpotent ligand. The conformational restriction pre-organises the binding geometry.

Why cyclisation matters

Linear α-MSH samples a broad conformational ensemble in solution. It pays an entropic penalty each time it docks into the orthosteric pocket of a melanocortin receptor. The Asp⁵–Lys¹⁰ amide bridge in MT-II pre-organises the His-D-Phe-Arg-Trp pharmacophore into a β-turn that mimics the receptor-bound conformation, reducing the conformational entropy lost on binding and raising apparent affinity across MC1R, MC3R, MC4R and MC5R [4].

The same constraint sterically shields the scissile bonds that endopeptidases would otherwise cleave — the structural basis for MT-II's longer plasma and tissue residence relative to α-MSH [4].

The D-Phe⁷ substitution

Inversion of stereochemistry at position 7 replaces L-Phe with D-Phe. This is the second decisive structure-activity relationship (SAR) feature. The D-isomer flips the aromatic side chain into an orientation that the receptor reads as the active rotamer, while simultaneously falling outside the substrate specificity pocket of proteases tuned for L-amino-acid substrates.

Combined with N-terminal acetylation and the Met⁴→Nle⁴ swap (which removes an oxidation-prone sulphur), the result is a peptide that is both more potent and more chemically stable than the endogenous hormone. The "superpotent cyclic melanotropin" designation entered the literature on the back of precisely these three modifications: Nle⁴ substitution, D-Phe⁷ inversion, and Asp⁵–Lys¹⁰ lactamisation.

This is a textbook case of constraint-driven SAR, and the same logic underwrites most modern cyclic peptide drug design. Related compounds are catalogued in our full peptides reference library.

Melanocortin Receptor Subtypes: MC1R to MC5R

Melanotan II is a non-selective agonist at four of the five melanocortin receptors (MC1R, MC3R, MC4R, MC5R), with negligible activity at MC2R. MC2R is ACTH-selective and structurally adapted to a different ligand pocket [1]. That pan-agonism explains why MT-II produces pigmentary, central, sexual and glandular effects in parallel — each receptor subtype controls a distinct physiological system — and why its adverse-effect profile mirrors its therapeutic interest [1][4].

The melanocortin receptors are class A rhodopsin-like GPCRs coupling primarily to Gαs and adenylate cyclase, raising intracellular cAMP on agonist binding. They share the His-Phe-Arg-Trp recognition motif present in α-MSH and locked into a β-turn by the Asp⁵–Lys¹⁰ lactam bridge of MT-II. This allows a single ligand to engage four subtypes whose extracellular loops and transmembrane pockets diverge considerably.

MC2R is the outlier. It requires the full ACTH(1-24) sequence and the accessory protein MRAP for trafficking. The truncated MT-II pharmacophore cannot productively activate it because the receptor's binding pocket is optimised for the longer ACTH peptide [1].

Receptor-tissue-function mapping

The clinical consequences track this map directly. MC1R activation drives the pigmentation that motivated unlicensed use. MC4R activation explains the spontaneous erections and nausea documented in the MHRA's pharmacovigilance record — 16 suspected adverse drug reactions between 1 January 2012 and 31 December 2022 [3]. This receptor controls both sexual arousal and the chemoreceptor trigger zone.

MC3R and MC5R engagement is implicated in the appetite, metabolic and sebaceous changes reported anecdotally and in animal work. The 2021 PACAP-deficient mouse study showed that MT-II partially rescued impaired thermogenesis, consistent with these receptors regulating energy expenditure [5].

No clinically deployed melanocortin agonist achieves true subtype selectivity at present. Afamelanotide (Scenesse), the licensed therapeutic analogue, is itself a broad agonist. Bremelanotide (PT-141), a metabolite-derived MC4R-preferring agent, retains residual activity at MC1R and MC5R [1]. Subtype-selective candidates are catalogued in our full peptides reference library.

How MT-II Triggers Melanogenesis: The MC1R Pathway

MT-II darkens skin by binding MC1R on melanocytes and driving a Gs-coupled cAMP cascade that ends in eumelanin deposition. The receptor is a class A GPCR that activates adenylyl cyclase upon agonist engagement, raising intracellular cAMP and switching on protein kinase A.

PKA then phosphorylates the cAMP-response element binding protein (CREB), which transactivates MITF, the master melanocyte transcription factor [1].

MITF upregulates the three rate-limiting melanogenic enzymes — tyrosinase, TYRP1 and DCT — inside melanosomes. Tyrosinase catalyses the conversion of L-tyrosine to DOPA and DOPAquinone, committing the pathway towards eumelanin (brown-black) rather than phaeomelanin (red-yellow) when cAMP tone is high and cysteine availability is low [1].

Mature melanosomes then traffic along dendrites and transfer to surrounding keratinocytes, producing the visible facultative pigmentation observed clinically.

This is the same axis that endogenous α-MSH activates following UV-induced p53 signalling in keratinocytes. MT-II is often described as a pharmacological mimic of the tanning response without the preceding DNA damage that triggers it physiologically. The distinction matters: UV both drives melanogenesis and generates the cyclobutane pyrimidine dimers that the pigment is meant to mitigate. MT-II drives pigmentation without the upstream genotoxic stimulus, bypassing the p53-dependent signalling cascade entirely [1].

Dose-response evidence

The earliest controlled human pharmacodynamic data come from Dorr and colleagues at Arizona in 1996. They reported measurable increases in cutaneous melanin density after five subcutaneous doses of MT-II administered every other day in healthy volunteers, with darkening sustained for several weeks post-dosing [1]. Subsequent reviews converge on the same cAMP/MITF/tyrosinase mechanism as the proximate driver of the phenotype, which is conserved across mammalian melanocytes [2].

The cyclic lactam constraint makes this pathway clinically efficient at low microgram doses. Receptor residence time at MC1R extends relative to linear α-MSH, prolonging cAMP elevation per binding event because the constrained backbone remains bound longer before dissociating. Structurally adjacent melanocortin analogues are catalogued in our full peptides reference library.

MC4R and MC3R: Behavioural and Metabolic Effects

The non-cutaneous effects of melanotan 2 come from its agonism at MC4R and MC3R in the central nervous system, with MC5R activity producing a separate exocrine signal. Because the cyclic lactam scaffold is non-selective across the melanocortin family, every subcutaneous dose intended for MC1R-mediated pigmentation simultaneously stimulates these other subtypes [1][4].

MC4R is densely expressed in the hypothalamus and brainstem, where its activation produces the spontaneous penile erections and increased sexual arousal reported consistently in male users. This is the same circuit exploited by bremelanotide (PT-141), an MC4R-preferring analogue derived from MT-II and approved by the FDA in 2019 for hypoactive sexual desire disorder in premenopausal women. I have not identified any MHRA or EMA authorisation for bremelanotide as of 2026, so it functions as a mechanistic comparator rather than a UK-licensed reference product [1]. The Conversation's January 2025 commentary on MT-II flagged persistent erectile and priapism reports as a recurring adverse-effect signal traceable to this MC4R axis.

MC3R and MC4R together coordinate energy homeostasis, suppressing food intake and increasing energy expenditure. Both are co-expressed in the hypothalamic paraventricular nucleus. The 2021 mouse work by Bagdy and colleagues showed that MT-II partially rescued the thermogenic deficit in PACAP-deficient animals, consistent with central melanocortin tone driving brown adipose activity independently of pigmentation [4].

The appetite suppression and nausea reported anecdotally in human users map onto the same receptors, which is why MT-II has been discussed in non-clinical contexts as a putative anorectic.

MC5R is expressed in sebaceous and other exocrine glands. Its activation has been proposed as a mechanistic basis for the flushing and rosacea-like presentations occasionally documented in users, given MC5R's role in controlling sebaceous secretion and cutaneous blood flow. The supporting human evidence remains observational [1]. DermNet groups weight loss, aphrodisiac effects and sebaceous changes as the principal off-target consequences of pan-melanocortin agonism [1].

The adverse-effect profile of MT-II is not a contamination problem or an idiosyncratic toxicity. It is the predictable consequence of a non-selective agonist hitting four receptors the user did not intend to engage.

Reported Side Effects and Safety Evidence (2026)

The documented adverse-effect profile of melanotan 2 spans nausea and vomiting, facial flushing, spontaneous erections, fatigue, transient hypertension and, in severe case reports, cerebral oedema. The evidence base is dominated by case reports, small observational series and pharmacovigilance signals rather than adequately powered randomised controlled trials [2][5]. Most mechanisms map cleanly onto the pan-melanocortin agonism already described.

Nausea and vomiting are consistent with MC3R/MC4R signalling in the area postrema and hypothalamic feeding circuits — the same axis that produces the anorectic effect [4]. Facial flushing reflects melanocortin-driven cutaneous vasodilation via MC5R activation. Spontaneous and prolonged erections, including priapism, are MC4R-mediated, the pharmacology that motivated the development of bremelanotide from the MT-II scaffold [2].

Fatigue and blood-pressure changes have been reported in user surveys and clinical commentary but lack dose-response characterisation in humans.

The most serious signal is cerebral oedema, flagged in the January 2025 Conversation commentary alongside nausea, vomiting and erectile complications as a recurring presentation in emergency settings. The mechanism is not fully resolved and may reflect both direct central melanocortin effects and adulterant exposure from unregulated supply.

On the UK regulatory side, the MHRA FOI 24/274 disclosure recorded 16 suspected adverse drug reaction reports for Melanotan II products between 1 January 2012 and 31 December 2022, and stated that the agency had not made recommendations or taken specific action in response [1]. No 2024–2026 MHRA notice altering that position was located in the public record at the date of review [3]. DermNet continues to describe MT-II as "unlicensed and largely untested" [2], and the 2023 UNSW/TGA-aligned commentary reaches the same conclusion for the Australian market [5].

Two caveats matter for interpretation. First, the Ho et al. 2024 poster on user experience and the January 2025 Conversation piece are among the most current public-facing summaries; peer-reviewed safety literature beyond that point should be checked directly in PubMed or the MHRA Yellow Card scheme. Second, because UK supply is entirely unregulated, any reported toxicity carries an irreducible risk of contamination or mis-dosing on top of the intrinsic pharmacology. Readers cross-referencing related compounds can consult our full peptides reference library.

Regulatory Status in the UK and Globally (2026)

Melanotan 2 is an unlicensed medicinal product in the United Kingdom and is illegal to sell for human use, though it is not a controlled drug under the Misuse of Drugs Act 1971. Supplying it as a medicine without a marketing authorisation breaches the Human Medicines Regulations 2012, which is the legal instrument the MHRA has used to act against vendors. This page is a mechanistic and regulatory reference; it does not facilitate purchase.

Verified regulatory status (as of 2026)

The MHRA position is documented in FOI 24/274, which confirms the agency received 16 suspected adverse drug reaction reports for Melanotan II products between 1 January 2012 and 31 December 2022 and "has not made any recommendations or taken any specific actions" in response [2]. DermNet's clinical summary continues to describe MT-II as "unlicensed and largely untested" and notes that bremelanotide (PT-141) was derived from the same scaffold for erectile indications [3]. I did not identify any 2024–2026 MHRA instrument reclassifying Melanotan 2 under the Misuse of Drugs Act or altering its status under HMR 2012; verify the current position on the MHRA register [2].

In the EU, afamelanotide remains the sole authorised melanocortin analogue identified in the supplied evidence base [3]. No 2024–2026 EMA guidance specifically on unlicensed melanocortin analogues was located in this search. In Australia, the 2023 UNSW/TGA-aligned commentary frames Melanotan II as an unapproved medicine subject to enforcement against unlawful advertising and supply [1].

Readers consulting cognate compounds may find context in our full peptides reference library. Verify the MHRA position directly before any operational use of this summary.

Melanotan 2 vs Melanotan 1: Key Differences

Melanotan I (afamelanotide) is a linear 13-amino-acid α-MSH analogue licensed in the EU and UK as Scenesse (Clinuvel Pharmaceuticals) for erythropoietic protoporphyria. Melanotan II is an unlicensed cyclic 7-amino-acid lactam with broader, non-selective activity across the melanocortin receptor family [2]. Consumer-facing material routinely conflates the two. The structural and regulatory gap between them is the single most important distinction for anyone reading the primary literature.

The shorter MT-II scaffold is closed by a lactam bridge between Asp and Lys side chains, constraining the pharmacophore (His-DPhe-Arg-Trp) into the β-turn conformation that melanocortin receptors recognise. That conformational lock underlies both the superpotency and the loss of subtype selectivity discussed earlier.

Afamelanotide retains the linear α-MSH backbone with a single DPhe⁷ substitution and the Nle⁴ replacement, which preserves a more α-MSH-like binding profile and tilts activity towards MC1R-driven eumelanin synthesis [2].

Comparison at a glance

The licensing asymmetry is not a technicality. Afamelanotide passed EMA scrutiny for a defined photodermatosis indication. MT-II has no equivalent dossier in any jurisdiction surveyed here [2][5]. The broader peptides reference library situates both compounds among related melanocortin and hypothalamic analogues.

Research Context: What Studies Have Been Conducted?

The human evidence base for melanotan 2 is thin, dated, and dominated by small early-phase work rather than registrational trials. The foundational study remains Dorr et al. 1996, a subcutaneous tanning trial in a small cohort over five doses. It established proof-of-concept pigmentation but was never followed by an adequately powered Phase III programme — no pharmaceutical sponsor pursued development beyond early proof-of-concept. No Phase II or Phase III MT-II trial was identified in the ClinicalTrials.gov or ISRCTN record between 2023 and 2026 at the date of review.

Subsequent literature is largely preclinical. Receptor-binding and functional assay papers from the late 1990s and 2000s underpin the non-selective MC1R–MC5R agonist profile [3]. Recent rodent work continues in adjacent physiology: Bagdy and colleagues' 2021 demonstration that MT-II partially rescues impaired thermogenesis in PACAP-deficient mice speaks to MC3R/MC4R-mediated energy expenditure rather than pigmentation [1].

Human data outside controlled trials

Most contemporary human signal comes from off-label self-administration reports and pharmacovigilance returns rather than interventional studies. MT-II has never been licensed and therefore has no clinical trial infrastructure. The MHRA logged 16 suspected ADR reports between 1 January 2012 and 31 December 2022 [2]. Consumer-facing dermatology summaries such as DermNet's 2024 entry continue to be cited despite resting on the same older case series [3]. The Ho et al. 2024 conference poster contributed user-experience data but is not a controlled trial. Its progression to a full peer-reviewed paper could not be confirmed at the date of review.

Where the field is moving

Active academic interest has shifted to subtype-selective melanocortin agonists, particularly MC4R ligands for obesity and hypoactive sexual desire disorder, where bremelanotide provides the mechanistic template [3]. Related compounds are catalogued in our full peptides reference library. Treat any MT-II source predating 2023 as potentially stale.

Structural Genomics Perspective: What MT-II Teaches Us

Melanotan 2 is a textbook case for how backbone cyclisation and D-amino acid substitution rewrite a peptide's pharmacology without rewriting its pharmacophore. The His-Phe-Arg-Trp core of α-MSH is preserved. Replacing L-Phe with D-Phe and bridging Asp⁵ to Lys¹⁰ via a lactam locks the molecule into a β-turn conformation that resists proteolytic cleavage, presenting the message sequence to all five melanocortin receptors with nanomolar potency [2][4].

The cost of that conformational lock is selectivity: MT-II reads as agonist at MC1R through MC5R rather than discriminating between them [4].

Cyclisation as a design principle

The MT-II scaffold predates most modern structure-based peptide design, but the lesson generalises. Constraining rotational freedom around a pharmacophore raises binding affinity by reducing the entropic penalty of receptor engagement. D-amino acids at scissile bonds block aminopeptidase recognition because the altered stereochemistry falls outside the enzyme's substrate pocket. Both moves extend plasma half-life relative to linear α-MSH [2].

From non-selective tool to selective successors

MT-II's promiscuity across MC3R, MC4R and MC5R is precisely what made it useful as a probe and precisely what limited its therapeutic ceiling. Mapping which side-chain contacts drive MC1R pigmentation versus MC4R appetite signalling enabled the next generation of subtype-selective ligands, of which bremelanotide is the closest structural descendant [2]. For readers tracing these binding principles further, our full peptides reference library catalogues related cyclic and constrained analogues alongside their target receptors.

Next Steps

If you are researching melanocortin pharmacology for academic or clinical purposes, consult the MHRA Yellow Card scheme directly for the most current UK adverse-event data, and cross-reference PubMed for peer-reviewed literature published after 2023. For related melanocortin analogues, explore our full peptides reference library. If you have concerns about exposure to melanotan 2 or related compounds, contact your GP or the UK's National Poisons Information Service.